L-homoarginine is associated with decreased cardiovascular- and all-cause mortality.
L-homoarginine
South Africa
all-cause mortality
cardiovascular disease
nitric oxide
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
10
12
2020
received:
20
10
2020
accepted:
10
12
2020
pubmed:
16
12
2020
medline:
15
12
2021
entrez:
15
12
2020
Statut:
ppublish
Résumé
Increasing evidence suggests that L-homoarginine, an endogenous analogue of the amino acid L-arginine, may have beneficial effects on vascular homeostasis. We examined whether L-homoarginine is associated with 10-year risk of all-cause and cardiovascular mortality in a black South African population. We included 669 black South African participants (mean age 59.5 years), 143 of whom died during the 10-year follow-up period. Mortality data were acquired via verbal autopsy. Plasma L-homoarginine (and other related markers) were analysed with liquid chromatography-tandem mass spectrometry. Survivors had higher L-homoarginine levels compared with nonsurvivors (1.25 µM vs. 0.89 µM; P < .001). Multivariable Cox regression analyses revealed that higher plasma L-homoarginine predicted a reduction in 10-year cardiovascular (hazard ratio [HR] per SD increment, 0.61; 95% CI 0.50 to 0.75) and all-cause (hazard ratio [HR] per SD increment, 0.59; 95% CI 0.41 to 0.84) mortality risk. Higher L-homoarginine levels are associated with reduced risk of 10-year cardiovascular and all-cause mortality. Regulation of L-homoarginine levels as a therapeutic target in the management of cardiovascular disease should be investigated.
Sections du résumé
BACKGROUND
BACKGROUND
Increasing evidence suggests that L-homoarginine, an endogenous analogue of the amino acid L-arginine, may have beneficial effects on vascular homeostasis. We examined whether L-homoarginine is associated with 10-year risk of all-cause and cardiovascular mortality in a black South African population.
METHODS
METHODS
We included 669 black South African participants (mean age 59.5 years), 143 of whom died during the 10-year follow-up period. Mortality data were acquired via verbal autopsy. Plasma L-homoarginine (and other related markers) were analysed with liquid chromatography-tandem mass spectrometry.
RESULTS
RESULTS
Survivors had higher L-homoarginine levels compared with nonsurvivors (1.25 µM vs. 0.89 µM; P < .001). Multivariable Cox regression analyses revealed that higher plasma L-homoarginine predicted a reduction in 10-year cardiovascular (hazard ratio [HR] per SD increment, 0.61; 95% CI 0.50 to 0.75) and all-cause (hazard ratio [HR] per SD increment, 0.59; 95% CI 0.41 to 0.84) mortality risk.
CONCLUSION
CONCLUSIONS
Higher L-homoarginine levels are associated with reduced risk of 10-year cardiovascular and all-cause mortality. Regulation of L-homoarginine levels as a therapeutic target in the management of cardiovascular disease should be investigated.
Substances chimiques
Homoarginine
156-86-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13472Subventions
Organisme : German Academic Exchange Service
Organisme : South Africa - Netherlands Research Program on Alternatives in Development
Organisme : South African NRF National Research Foundation
ID : 2069139
Organisme : South African NRF National Research Foundation
ID : FA2006040700010
Organisme : Population Health Research Institute
Organisme : Medical Research Council of South Africa
Organisme : North-West University
Informations de copyright
© 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.
Karetnikova ES, Jarzebska N, Markov AG, Weiss N, Lentz SR, Rodionov RN. Is homoarginine a protective cardiovascular risk factor? Arterioscler Thromb Vascul Biol. 2019;118(31):2218.
Zinellu A, Paliogiannis P, Carru C, Mangoni AA. Homoarginine and all-cause mortality: a systematic review and meta-analysis. Eur J Clin Invest. 2018;48(8):e12960.
Ryan W, Johnson R, Dimari S. Homoarginine synthesis by rat kidney. Arch Biochem Biophys. 1969;131(2):521-526.
Marescau B, Nagels G, Possemiers I, et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism. 1997;46(9):1024-1031.
Mizutani N, Hayakawa C, Ohya Y, Watanabe K, Watanabe Y, Mori A. Guanidino compounds in hyperargininemia. Tohoku J Exp Med. 1987;153(3):197-205.
Hrabak A, Bajor T, Temesi A. Comparison of substrate and inhibitor specificity of arginase and nitricm oxide (NO) synthase for arginine analogs and related compounds in murine and rat macrophages. Biochem Biophys Res Comm. 1994;198(1):206-212.
Moali C, Boucher JL, Sari MA, Stuehr DJ, Mansuy D. Substrate specificity of NO synthases: detailed comparison of l-arginine, homo-l-arginine, their N ω-hydroxy derivatives, and N ω-hydroxynor-l-arginine. Biochemistry. 1998;37(29):10453-10460.
Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res. 2009;60(6):448-460.
Bode-Böger SM, Scalera F, Kielstein JT, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17(4):1128-1134.
Atzler D, McAndrew DJ, Cordts K, et al. Dietary supplementation with homoarginine preserves cardiac function in a murine model of post-myocardial infarction heart failure. Circulation. 2017;135(4):400-402.
Dellera F, Ganzetti GS, Froio A, et al. L-homoarginine administration reduces neointimal hyperplasia in balloon-injured rat carotids. Thromb Haemost. 2016;116(08):400-402.
Pilz S, Meinitzer A, Gaksch M, et al. Homoarginine in the renal and cardiovascular systems. Amino Acids. 2015;47(9):1703-1713.
Kayacelebi AA, Nguyen TH, Neil C, Horowitz JD, Jordan J, Tsikas D. Homoarginine and 3-nitrotyrosine in patients with takotsubo cardiomyopathy. Int J Cardiol. 2014;173(3):546-547.
Haghikia A, Yanchev GR, Kayacelebi AA, et al. The role of L-arginine/L-homoarginine/nitric oxide pathway for aortic distensibility and intima-media thickness in stroke patients. Amino Acids. 2017;49(6):1111-1121.
Pilz S, Teerlink T, Scheffer PG, et al. Homoarginine and mortality in an older population: the H oorn study. Eur J Clin Invest. 2014;44(2):200-208.
März W, Meinitzer A, Drechsler C, et al. Homoarginine, cardiovascular risk, and mortality. Circulation. 2010;122(10):967-975.
Pilz S, Tomaschitz A, Meinitzer A, et al. Low serum homoarginine is a novel risk factor for fatal strokes in patients undergoing coronary angiography. Stroke. 2011;42(4):1132-1134.
Drechsler C, Meinitzer A, Pilz S, et al. Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients. Eur J Heart Fail. 2011;13(8):852-859.
Atzler D, Gore MO, Ayers CR, et al. Homoarginine and cardiovascular outcome in the population-based Dallas Heart Study. Arterioscler Thromb Vasc Biol. 2014;34(11):2501-2507.
Stats S. Mortality and causes of death in South Africa, 2016: Findings from death notification. Pretoria, South Africa: Stats SA; 2014.
deGoma EM, Knowles JW, Angeli F, Budoff MJ, Rader DJ. The evolution and refinement of traditional risk factors for cardiovascular disease. Cardiology in review. 2012;20(3):118.
Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009;158(1):1-7.e1.
Schutte AE, Schutte R, Huisman HW, et al. Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in Black South Africans? A 5-year prospective study. Int J Epidemiol. 2012;41(4):1114-1123.
Marfell-Jones M, Stewart A, de Ridder J. International standards for anthropometric assessment. 2012.
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104.
Atzler D, Mieth M, Maas R, Böger RH, Schwedhelm E. Stable isotope dilution assay for liquid chromatography-tandem mass spectrometric determination of l-homoarginine in human plasma. J Chromatogr B. 2011;879(23):2294-2298.
Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B. 2007;851(1):211-219.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
Atlas D, International Diabetes Federation. IDF diabetes Atlas, 7th edn. Brussels, Belgium: International Diabetes Federation; 2015.
Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29.
Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40(1):35-53.
Atzler D, Appelbaum S, Cordts K, et al. Reference intervals of plasma homoarginine from the German Gutenberg Health Study. Clin Chem Lab Med (CCLM). 2016;54(7):1231-1237.
Schwedhelm E, Song RJ, Ramachandran VS, et al. Association of lower plasma homoarginine concentrations with greater risk of all-cause mortality in the community: the framingham offspring study. J Clin Med. 2020;9(6):2016.
Atzler D, Rosenberg M, Anderssohn M, et al. Homoarginine-an independent marker of mortality in heart failure. Int J Cardiol. 2013;168(5):4907-4909.
Michel T. R is for arginine: metabolism of arginine takes off again, in new directions. Am Heart Assoc. 2013;128(13):1400-1404.
Tommasi S, Elliot DJ, Da Boit M, Gray SR, Lewis BC, Mangoni AA. Homoarginine and inhibition of human arginase activity: kinetic characterization and biological relevance. Sci Rep. 2018;8(1):1-13.
Karetnikova ES, Jarzebska N, Markov AG, Weiss N, Lentz SR, Rodionov RN. Is homoarginine a protective cardiovascular risk factor? Arterioscler Thromb Vasc Biol. 2019;39(5):869-875.
Mokhaneli MC, Fourie CM, Botha-Le Roux S, Böger RH, Schwedhelm E, Mels CM. Asymmetric dimethylarginine and l-homoarginine prospectively relate to carotid wall thickness in a South African cohort. Amino Acids. 2020;52(6-7):965-973.
Choe C, Atzler D, Wild PS, et al. Homoarginine levels are regulated by l-arginine: glycine amidinotransferase and affect stroke outcome results from human and murine studies. Circulation. 2013;128(13):1451-1461.
Alesutan I, Feger M, Tuffaha R, et al. Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine. Cardiovasc Res. 2016;110(3):408-418.
Kakoki M, Kim HS, Arendshorst WJ, Mattson DL. L-Arginine uptake affects nitric oxide production and blood flow in the renal medulla. Am J Physiol Regul Integr Comp Physiol. 2004;287(6):R1478-R1485.
Chen PY, Sanders PW. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension. 1993;22(6):812-818.
Atzler D, Schönhoff M, Cordts K, et al. Oral supplementation with L-homoarginine in young volunteers. Br J Clin Pharmacol. 2016;82(6):1477-1485.
Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine (ADMA) and incidence of cardiovascular disease and mortality in the community. Circulation. 2009;119(12):1592.
Schulze F, Carter AM, Schwedhelm E, et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis. 2010;208(2):518-523.
Siegerink B, Maas R, Vossen C, et al. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: The KAROLA follow-up study. Clin Res Cardiol. 2012;102(3):193-202.
Willeit P, Freitag DF, Laukkanen JA, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4(6):e001833.
Gore MO, Lüneburg N, Schwedhelm E, et al. Symmetrical dimethylarginine predicts mortality in the general population observations from the Dallas heart study. Arterioscler Thromb Vasc Biol. 2013;33(11):2682-2688.
Schutte AE, Schutte R, Huisman HW, et al. Dimethylarginines: their vascular and metabolic roles in Africans and Caucasians. Eur J Endocrinol. 2010;162(3):525-533.
Reimann M, Schutte A, Malan N, et al. Asymmetric dimethylarginine is associated with parameters of glucose metabolism in Caucasian but not in African women from South Africa. Exp Clin Endocrinol Diabetes. 2007;115(09):600-605.
Nojilana B, Bradshaw D, Pillay-van Wyk V, et al. Persistent burden from non-communicable diseases in South Africa needs strong action. S Afr Med J. 2016;106(5):436-437.